Gilgamesh Pharmaceuticals

Clinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders.  As recently...

Psychedelics biotech company Gilgamesh Pharmaceuticals announced the closing of a $39 million Series B financing round led by Prime Movers Lab and joined by Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures.  The new funding, which adds to the $27...

Private psychedelics biotech company Gilgamesh Pharmaceuticals is currently developing a diverse portfolio of novel, potentially first-in-class compounds targeting mechanisms with demonstrated clinical efficacy, onset duration or prolonged treatment duration, for the treatment of psychiatric...

Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round led by Prime Movers Lab. Other investors involved in the round included the Noetic Psychedelic Fund LP...